Karyopharm Therapeutics, Inc.
(NASDAQ : KPTI)

( )
KPTI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corp.
0.10%108.241.3%$1607.19m
AMGNAmgen, Inc.
1.02%227.821.3%$571.14m
BIIBBiogen, Inc.
1.07%288.461.4%$565.61m
GILDGilead Sciences, Inc.
1.31%65.731.0%$410.71m
ILMNIllumina, Inc.
-0.65%312.853.5%$332.16m
VRTXVertex Pharmaceuticals, Inc.
0.20%215.501.9%$314.83m
REGNRegeneron Pharmaceuticals, Inc.
1.90%350.782.6%$287.08m
EXASEXACT Sciences Corp.
-5.85%79.0224.0%$211.83m
ALXNAlexion Pharmaceuticals, Inc.
0.92%109.532.0%$182.47m
BMRNBioMarin Pharmaceutical, Inc.
-0.47%77.074.3%$133.99m
SRPTSarepta Therapeutics, Inc.
1.83%104.1714.6%$129.42m
SGENSeattle Genetics, Inc.
-0.78%119.906.1%$124.30m
AAgilent Technologies, Inc.
-0.28%78.301.6%$105.86m
BGNEBeiGene Ltd.
2.47%208.342.1%$96.02m
NBIXNeurocrine Biosciences, Inc.
0.59%113.755.0%$93.68m

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.